Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.

Kline JA, Yealy DM.

Nat Rev Cardiol. 2012 May 8;9(7):378-80. doi: 10.1038/nrcardio.2012.65. No abstract available.

PMID:
22566060
2.

[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].

Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sié P.

J Mal Vasc. 2012 Dec;37(6):300-10. doi: 10.1016/j.jmv.2012.09.003. Epub 2012 Nov 2. French.

PMID:
23122646
3.

[Advances in venous thromboembolism].

Qin L, Lu WX.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 May;36(5):372-4. Review. Chinese. No abstract available.

PMID:
24047815
4.

[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].

Einecke D.

MMW Fortschr Med. 2012 Apr 19;154(7):24. German. No abstract available.

PMID:
22558862
5.
6.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A.

N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.

7.

New oral anticoagulants for acute venous thromboembolism.

[No authors listed]

Med Lett Drugs Ther. 2014 Jan 6;56(1433):3-4. No abstract available.

PMID:
24419296
8.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

9.

Rivaroxaban for thromboprophylaxis.

Lotke PA.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009675
10.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

11.

Rivaroxaban, the first oral, direct factor Xa inhibitor.

Fassiadis N.

Expert Opin Pharmacother. 2009 Dec;10(18):2945-6. doi: 10.1517/14656560903413559.

PMID:
19925048
12.

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Fermann GJ, Erkens PM, Prins MH, Wells PS, Pap ÁF, Lensing AW.

Acad Emerg Med. 2015 Mar;22(3):299-307. doi: 10.1111/acem.12615. Epub 2015 Feb 25.

13.

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

Romualdi E, Donadini MP, Ageno W.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):841-4. doi: 10.1586/erc.11.62.

PMID:
21809964
14.

Oral rivaroxaban for symptomatic venous thromboembolism.

Landman GW, Gans RO.

N Engl J Med. 2011 Mar 24;364(12):1178; author reply 1178. doi: 10.1056/NEJMc1100734#SA1. No abstract available.

PMID:
21428778
15.

Rivaroxaban for treatment of venous thromboembolism in older adults.

Mitchell AP, Conway SE.

Consult Pharm. 2014 Sep;29(9):627-30. doi: 10.4140/TCP.n.2014.627. Review.

PMID:
25203412
16.

Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.

Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.

Acad Emerg Med. 2015 Feb;22(2):142-9. doi: 10.1111/acem.12585. Epub 2015 Feb 9.

17.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Cao YB, Zhang JD, Shen H, Jiang YY.

Eur J Clin Pharmacol. 2010 Nov;66(11):1099-108. doi: 10.1007/s00228-010-0889-z. Epub 2010 Sep 2.

PMID:
20812009
18.

Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.

Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E.

Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6. Review.

PMID:
25037495
19.

New oral anticoagulants for the treatment of venous thromboembolism.

Agnelli G, Becattini C, Franco L.

Best Pract Res Clin Haematol. 2013 Jun;26(2):151-61. doi: 10.1016/j.beha.2013.07.005. Epub 2013 Jul 22. Review.

PMID:
23953903
20.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186

Supplemental Content

Support Center